These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32823598)

  • 1. Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors.
    Pinto DO; DeMarino C; Vo TT; Cowen M; Kim Y; Pleet ML; Barclay RA; Noren Hooten N; Evans MK; Heredia A; Batrakova EV; Iordanskiy S; Kashanchi F
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32823598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.
    Martin AR; Pollack RA; Capoferri A; Ambinder RF; Durand CM; Siliciano RF
    J Clin Invest; 2017 Feb; 127(2):651-656. PubMed ID: 28094770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4
    Wen J; Li X; Zhao QX; Yang XF; Wu ML; Yan Q; Chang J; Wang H; Jin X; Su X; Deng K; Chen L; Wang JH
    Emerg Microbes Infect; 2022 Dec; 11(1):391-405. PubMed ID: 34985411
    [No Abstract]   [Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curaxin CBL0137 has the potential to reverse HIV-1 latency.
    Jean MJ; Zhou D; Fiches G; Kong W; Huang H; Purmal A; Gurova K; Santoso NG; Zhu J
    J Med Virol; 2019 Aug; 91(8):1571-1576. PubMed ID: 30989696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4
    Cao S; Slack SD; Levy CN; Hughes SM; Jiang Y; Yogodzinski C; Roychoudhury P; Jerome KR; Schiffer JT; Hladik F; Woodrow KA
    Sci Adv; 2019 Mar; 5(3):eaav6322. PubMed ID: 30944862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
    Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway.
    Barclay RA; Mensah GA; Cowen M; DeMarino C; Kim Y; Pinto DO; Erickson J; Kashanchi F
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32575590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Current Status of Latency Reversing Agents for HIV-1 Remission.
    Rodari A; Darcis G; Van Lint CM
    Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    Macedo AB; Levinger C; Nguyen BN; Richard J; Gupta M; Cruz CRY; Finzi A; Chiappinelli KB; Crandall KA; Bosque A
    J Virol; 2022 Aug; 96(15):e0037222. PubMed ID: 35867565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
    Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
    Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.
    Iordanskiy S; Kashanchi F
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):120-4. PubMed ID: 26765533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
    Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
    Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective cell death of latently HIV-infected CD4
    Zhang G; Luk BT; Wei X; Campbell GR; Fang RH; Zhang L; Spector SA
    Cell Death Dis; 2019 May; 10(6):419. PubMed ID: 31142734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.